eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

vol. 43
Experimental immunology

Neutralizing TGF-β promotes anti-tumor immunity of dendritic cells against pancreatic cancer by regulating T lymphocytes

Ning Pu, Guochao Zhao, Shanshan Gao, Yutong Cui, Yadong Xu, Yang Lv, Abulimiti Nuerxiati, Wenchuan Wu

(Centr Eur J Immunol 2018; 43 (2): 123-131)
Online publish date: 2018/06/30
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Previous fundamental or clinical trials of dendritic cell (DC) vaccine against pancreatic ductal adeno­carcinoma (PDAC) revealed the burgeoning neoadjuvant immunotherapy. Microarray studies indicated that multiple ingredients of the transfer growth factor beta (TGF-) pathway were over­expressed in PDAC, which inhibited the intratumoral immune response. To explore whether the DC volume in tumor microenvironment contributes to the differentiation of T cell cohort and test the hypo­thesis that combining DC vaccine with TGF- inhibitors will elevate the anti-tumor immune response, we managed to co-culture T cells in vitro with pancreatic cancer cells and DCs in different concentrations, and combine TGF- blockage with DC vaccine therapy in a murine model of pancreatic cancer. In in vitro studies, we discovered that CD8+ T cytotoxic cell (Tc) presented a significant advantage and lower volume of CD4+ T helper cell (Th) existed with a certain elevated DC concentration (p < 0.05), associated with declined interleukin (IL)-10 and increased interferon (IFN)-, which suggested with the DC volume increasing, the enhancing immune effect may represent a great advantage in such a system (p < 0.05). When interfered with anti-TGF- antibody or TGF- cytokine, respectively, in the co-culture system, we found IFN- producing was extremely higher and T cell apoptosis relatively descent with TGF- blockage (p < 0.05). The murine PDAC model demonstrated a survival advantage treated with anti-TGF- antibody combined with DC vaccine when compared with monotherapy controls (p < 0.05). Therefore, these findings indicated that, through neutralizing TGF- associated with DC vaccine, the anti-tumor immunity is highly elevated and this combinational therapy will provide an efficacious prospect.

pancreatic ductal adenocarcinoma, DCs, TGF-beta, immunotherapy, prognosis

Martin RC 2nd, McFarland K, Ellis S, et al. (2012): Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg 215: 361-369.
Thanos L, Poulou LS, Mailli L, et al. (2010): Image-guided radiofrequency ablation of a pancreatic tumor with a new triple spiral-shaped electrode. Cardiovasc Intervent Radiol 33: 215-218.
Carrafiello G, Ierardi AM, Fontana F, et al. (2013): Microwave ablation of pancreatic head cancer: safety and efficacy. J Vasc Interv Radiol 24: 1513-1520.
Casadei R, Ricci C, Pezzilli R, et al. (2010): A prospective study on radiofrequency ablation locally advanced pancreatic cancer. Hepatobiliary Pancreat Dis Int 9: 306-311.
Carrafiello G, Ierardi AM, Piacentino F, et al. (2012): Microwave ablation with percutaneous approach for the treatment of pancreatic adenocarcinoma. Cardiovasc Intervent Radiol 35: 439-442.
Siegel RL, Miller KD, Jemal A (2016): Cancer statistics, 2016. CA Cancer J Clin 66: 7-30.
Ino Y, Yamazaki-Itoh R, Shimada K, et al. (2013): Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 108: 914-923.
Protti MP, De Monte L (2013): Immune infiltrates as predictive markers of survival in pancreatic cancer patients. Front Physiol 4: 210.
Kotteas E, Saif MW, Syrigos K (2016): Immunotherapy for pancreatic cancer. J Cancer Res Clin Oncol 142: 1795-1805.
Liu L, Zhao G, Wu W, et al. (2016): Low intratumoral regulatory T cells and high peritumoral CD8(+) T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy. Cancer Immunol Immunother 65: 73-82.
Tang Y, Xu X, Guo S, et al. (2014): An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PLoS One 9: e91551.
Chen X, Du Y, Huang Z (2012): CD4+CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity. Immunol Lett 148: 83-89.
Ikushima H, Miyazono K (2010): TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 10: 415-424.
Ijichi H. (2004): TGF-beta signaling pathway in pancreatic cancer cells. Nihon Rinsho 62: 1241-1248.
Inaba K, Inaba M, Romani N, et al. (1992): Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony- stimulating factor. J Exp Med 176: 1693-1702.
Kosmaczewska A, Ciszak L, Potoczek S, et al. (2008): The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp (Warsz) 56: 181-191.
Khazaie K, von Boehmer H (2006): The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Biol 16: 124-136.
Yamamoto T, Yanagimoto H, Satoi S, et al. (2012): Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas 41: 409-415.
Xiang ST, Zhou SW, Guan W, et al. (2005): Expression of MUC1 and distribution of tumor-infiltrating dentritic cells in human bladder transitional cell carcinoma. Di Yi Jun Yi Da Xue Xue Bao 25: 1114-1118.
Soruri A, Fayyazi A, Neumann C, et al. (2001): Ex vivo generation of human anti-melanoma autologous cytolytic T cells by dentritic cell/melanoma cell hybridomas. Cancer Immunol Immunother 50: 307-314.
Bhairavabhotla RK, Verm V, Tongaonkar H, et al. (2007): Role of IL-10 in immune suppression in cervical cancer. Indian J Biochem Biophys 44: 350-356.
Kindlund B, Sjoling A, Yakkala C, et al. (2017): CD4+ regulatory T cells in gastric cancer mucosa are proliferating and express high levels of IL-10 but little TGF-beta. Gastric Cancer 20: 116-125.
Fullerton PT Jr., Creighton CJ, Matzuk MM (2015): Insights Into SMAD4 Loss in Pancreatic Cancer From Inducible Restoration of TGF-beta Signaling. Mol Endocrinol 29: 1440-1453.
Truty MJ, Urrutia R (2007): Basics of TGF-beta and pancreatic cancer. Pancreatology 7: 423-435.
Javle M, Li Y, Tan D, et al. (2014): Biomarkers of TGF-beta signaling pathway and prognosis of pancreatic cancer. PLoS One 9: e85942.
Soares KC, Rucki AA, Kim V, et al. (2015): TGF-beta blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner. Oncotarget 6: 43005-43015.
Greco SH, Tomkotter L, Vahle AK, et al. (2015): TGF-beta Blockade Reduces Mortality and Metabolic Changes in a Validated Murine Model of Pancreatic Cancer Cachexia. PLoS One 10: e0132786.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe